DOCSLIB.ORG

BOOK of ABSTRACTS OXFORD ENCALS Meeting 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BOOK of ABSTRACTS OXFORD ENCALS Meeting 2018 2018 MEETING 20-22 JUNE 2018 BOOK OF ABSTRACTS OXFORD ENCALS Meeting 2018 Acknowledgements ENCALS would like to thank the following sponsors for their generous support of this year’s meeting. Gold Sponsor Silver Sponsors Bronze Sponsors 2 ENCALS Meeting 2018 Poster Session 1: Wednesday 20th June, 18:00 - 19:30 Entrance Hall: A01 Hot-spot KIF5A mutations cause familial ALS David Brenner* (1), Rüstem Yilmaz (1), Kathrin Müller (1), Torsten Grehl (2), Susanne Petri (3), Thomas Meyer (4), Julian Grosskreutz (5), Patrick Weydt (1, 6), Wolfgang Ruf (1), Christoph Neuwirth (7), Markus Weber (7), Susana Pinto (8, 9), Kristl G. Claeys (10, 11, 12), Berthold Schrank (13), Berit Jordan (14), Antje Knehr (1), Kornelia Günther (1), Annemarie Hübers (1), Daniel Zeller (15), The German ALS network MND-NET, Christian Kubisch (16, 17), Sibylle Jablonka (18), Michael Sendtner (18), Thomas Klopstock (19), Mamede de Carvalho (8, 20), Anne Sperfeld (14), Guntram Borck (16), Alexander E. Volk (16, 17), Johannes Dorst (1), Joachim Weis (10), Markus Otto (1), Joachim Schuster (1), Kelly del Tredici (1), Heiko Braak (1), Karin M. Danzer (1), Axel Freischmidt (1), Thomas Meitinger (21), Tim M. Strom (21), Albert C. Ludolph (1), Peter M. Andersen (1, 9), and Jochen H. Weishaupt (1) Heterozygous missense mutations in the N-terminal motor or coiled-coil domains of the kinesin family member 5A (KIF5A) gene cause monogenic spastic paraplegia (HSP10) and Charcot-Marie-Tooth disease type 2 (CMT2). Moreover, heterozygous de novo frame-shift mutations in the C-terminal domain of KIF5A are associated with neonatal intractable myoclonus, a neurodevelopmental syndrome. These findings, together with the observation that many of the disease genes associated with amyotrophic lateral sclerosis disrupt cytoskeletal function and intracellular transport, led us to hypothesize that mutations in KIF5A are also a cause of amyotrophic lateral sclerosis. Using whole exome sequencing followed by rare variant analysis of 426 patients with familial amyotrophic lateral sclerosis and 6137 control subjects, we detected an enrichment of KIF5A splice-site mutations in amyotrophic lateral sclerosis (2/426 compared to 0/6137 in controls; P = 4.2 × 10−3), both located in a hot-spot in the C-terminus of the protein and predicted to affect splicing exon 27. We additionally show co-segregation with amyotrophic lateral sclerosis of two canonical splice-site mutations in two families. Investigation of lymphoblast cell lines from patients with KIF5A splice-site mutations revealed the loss of mutant RNA expression and suggested haploinsufficiency as the most probable underlying molecular mechanism. Furthermore, mRNA sequencing of a rare non-synonymous missense mutation (predicting p.Arg1007Gly) located in the C-terminus of the protein shortly upstream of the splice donor of exon 27 revealed defective KIF5A pre-mRNA splicing in respective patient-derived cell lines owing to abrogation of the donor site. Finally, the non-synonymous single nucleotide variant 3 ENCALS Meeting 2018 rs113247976 (minor allele frequency = 1.00% in controls, n = 6137), also located in the C-terminal region [p.(Pro986Leu) in exon 26], was significantly enriched in familial amyotrophic lateral sclerosis patients (minor allele frequency = 3.40%; P = 1.28 × 10−7). Our study demonstrates that mutations located specifically in a C-terminal hotspot of KIF5A can cause a classical amyotrophic lateral sclerosis phenotype, and underline the involvement of intracellular transport processes in amyotrophic lateral sclerosis pathogenesis. 1) Neurology Department, Ulm University, Ulm, Germany. 2) Department of Neurology, Alfried Krupp Hospital, Essen, Germany. 3) Department of Neurology, Hannover Medical School, Hannover, Germany. 4) Charité University Hospital, Humboldt-University, Berlin, Germany. 5) Department of Neurology, Jena University Hospital, Jena, Germany. 6) Department for Neurodegenerative Disorders and Gerontopsychiatry, Bonn University, Bonn, Germany. 7) Kantonsspital St. Gallen, ALS Outpatient Clinic, St. Gallen, Switzerland. 8) Department of Neurosciences and Mental Health, Hospital de Santa Maria-CHLN, Lisbon, Portugal. 9) Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden. 10) Institute of Neuropathology, RWTH Aachen University Hospital, Aachen, Germany. 11) Department of Neurology, RWTH Aachen University Hospital, Aachen, Germany. 12) Department of Neurology, University Hospitals Leuven, Leuven, Belgium. Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, Experimental Neurology, KU Leuven – University of Leuven, Leuven, Belgium. 13) Department of Neurology, DKD HELIOS Klinik Wiesbaden, Wiesbaden, Germany. 14) Department of Neurology Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany. 15) Department of Neurology, University of Würzburg, Würzburg, Germany. 16) Institute of Human Genetics, Ulm University, Ulm, Germany. 17) Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 18) Institute of Clinical Neurobiology, University Hospital of Würzburg, Würzburg, Germany. 19) Department of Neurology with Friedrich-Baur-Institute, University of Munich, Munich, Germany. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 20) Instituto de Medicina Molecular and Institute of Physiology, Faculty of Medicine, University of Lisbon, Portugal. 21) SyNergy, Munich Cluster for Systems Neurology, Ludwig Maximilians Universität München, Germany. Institute of Human Genetics, Technische Universität München, München, Germany. 4 ENCALS Meeting 2018 A02 Alterations of C9orf72, SOD1, TARDBP, FUS and UBQLN2 genes with amyotrophic lateral sclerosis Vildan Çiftçi 1, Türker Bilgen 2, Şule Darbaş 1, Yunus Arıkan 1, Hilmi Uysal 3*, Sibel Berker Karaüzüm 1 Objective: The aim of this study is to determine existence and frequency of the genomic alterations in C9orf72, SOD1, TARDBP, FUS and UBQLN2 genes which are frequently observed in familial(fALS) and sporadic(sALS) ALS diagnosed cases. Materials-Methods: Genomic DNA was isolated from peripheral blood in 12 fALS and 18 sALS. C9orf72 gene expansion was checked by triplet-primer PCR amplification and fragment analysis. All sequences encoding the SOD1, TARDBP, FUS and UBQLN2 genes were screened by DNA sequencing. Results: In intron1 of C9orf72 gene in 2 sALS cases c.-45+162_-45+163insGGGGCC heterozygote change was detected. In SOD1 gene in 2 fALS and 5 sALS heterozygote and in 1 sALS homozygote c.72+133C>T change in intron1; in 1 fALS novel c.169+41C>A heterozygote change in intron 2; in 3 fALS c.239+34A>C heterozygote change in intron 3 was found. In intron 5 of TARDBP gene in 6 cases c.714+67_714+68insG homozygote change was detected. In FUS gene mutation screening revealed c.147C>A change in exon3 with heterozygosity in 3 sALS, in exon4 c.291C>T change with heterozygosity in 5 fALS and 8 sALS and with homozygousity in 4 fALS and 8 sALS; also in intron 11 novel c.1067-61T>C heterozygote in 3 sALS and 1 fALS. In UBQLN2 gene 1 sALS novel c.1371G>C heterozygote change was determinated. Conclusion: C9orf72 hexanucleotide repeat expansion was observed 6,6% in 32 cases as known pathogenic mutation. In this study, three novel changes have been identified. Clinical significance of these changes is not yet known. The existence of variation in FUS gene in all cases supports that this gene is highly polymorphic. Keywords: ALS, sporadic ALS, familial ALS, genomic alterations 1) Akdeniz University Faculty of Medicine, Department of Medical Biology and Genetics, Antalya 2) Namık Kemal University, Health High School, Department of Nutrition and Dietetic, Tekirdağ 3) Akdeniz University Faculty of Medicine, Department of Neurology, Antalya 5 ENCALS Meeting 2018 A03 Novel ALS-associated mutations in the ARPP21 gene cause abnormal protein aggregation and altered neuronal morphology Chun Hao Wong (1)(*), Simon D Topp (1), Youn-Bok Lee (1), Sarah Mueller (1), Graham Cocks (1), Bradley N Smith (1), Nicola Ticozzi (2), John Landers (3), Christopher E Shaw (1) Background ALS is a highly heterogeneous neurodegenerative disease in which multiple, rare genetic causes may contribute. Here, we report a new disease- associated gene ARPP21 identified through whole-exome sequencing in a cohort of familial ALS cases. Two novel variants are shared by several unrelated index cases with no mutations in currently known ALS genes. To validate the involvement of ARPP21 in ALS, we have screened the gene extensively and studied the identified variants in cellular models. Materials and Methods Direct sequencing was performed on over 2000 ALS cases and 1000 controls of UK, US and Italian origin. Disease modelling was performed in HEK239T, SH-SY5Y and primary rat cortical neurons. Results Both variants linked with familial ALS (p.P563L; p.P747L) are replicated in a sporadic ALS cohort. The p.Proline563 residue is found to be substituted to glutamine in two sporadic cases of UK and Italian origin. These mutations are absent in both public databases and local control cohorts. Immunohistochemistry against the endogenous ARPP21 protein in human post-mortem cerebellum and spinal cord tissues suggests that it is a predominantly cytosolic phosphoprotein that is highly enriched in the neuronal population. Functional assays indicate that the ALS-associated mutations could cause disease hallmarks including enhanced detergent-insoluble aggregates, dysregulation
Load more

Recommended publications
  • Electrophysiological Changes in Patients with Impaired Glucose Tolerance
    Turkish Journal of Endocrinology and Metabolism, (2000) 4 : 123-128 ORIGINAL ARTICLE Electrophysiological Changes in Patients with Impaired Glucose Tolerance Serdar Güler* Dilek Berker** Hüseyin Tu¤rul Atasoy*** Bekir Çak›r** Hilmi Uysal*** Yalç›n Aral* Ankara Education and Research Hospital, Departments, Ankara, Turkey * Endocrinology and Metabolism ** Internal Medicine *** Neurology The effect of impaired glucose tolerance on neuropathy is not well characterized. This study is performed to clarify the status of peripheral neuropathy in patients with impaired glucose tolerance with no symptoms of neuropathy. Twenty-two patients with impaired glucose tolerance with no signs of neuropathy, and 11 healthy controls are examined with electromyoneurography. We have found electrophysiological changes in 13 of 22 patients with IGT, and in only one case of the 11 subjects in the control group. Mean H reflex latencies of the right and left medial vastus muscles were significantly longer in the patient group than the control group (17.0±1.7 vs. 15.6±2.5 msec, p<0,02; and 17.1±1.8 vs. 15.7±2.4 msec; p<0,01, respectively). Our results indicate that electrophysiological changes of the peripheral nerves are very common in patients with impaired glucose tolerance. Early diagnosis and mana- gement of impaired glucose tolerance may be particularly important in order to prevent the development of chronic complications. Key words: Impaired glucose tolerance, polyneuropathy, electromyoneurography, electrophysiological studies, electrophysiological abnormalities Introduction Activation of polyol pathway, nonenzymatic gly- cosylation, epineural vascular atherosclerosis, endo- Diabetes Mellitus (DM) is one of the most fre- neurial microvascular disease, dysfunction of endo- quent causes of peripheral neuropathy (1).
    [Show full text]
  • Neurological Complications of Cancer Immunotherapy
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2021 Neurological complications of cancer immunotherapy Roth, Patrick ; Winklhofer, Sebastian ; Müller, Antonia M S ; Dummer, Reinhard ; Mair, Maximilian J ; Gramatzki, Dorothee ; Le Rhun, Emilie ; Manz, Markus G ; Weller, Michael ; Preusser, Matthias Abstract: Immunotherapy has emerged as a powerful therapeutic approach in many areas of clinical on- cology and hematology. The approval of ipilimumab, a monoclonal antibody targeting the immune cell receptor CTLA-4, has marked the beginning of the era of immune checkpoint inhibitors. In the mean- time, numerous antibodies targeting the PD-1 pathway have expanded the class of clinically approved immune checkpoint inhibitors. Furthermore, novel antibodies directed against other immune checkpoints are currently in clinical evaluation. More recently, bispecific antibodies, which link T cells directly to tumor cells as well as adoptive T cell transfer with immune cells engineered to express a chimeric antigen receptor, have been approved in certain indications. Neurological complications associated with the use of these novel immunotherapeutic concepts have been recognized more and more frequently. Immune check- point inhibitors may cause various neurological deficits mainly by alterations of the peripheral nervous system’s integrity. These include radiculopathies, neuropathies, myopathies as well as myasthenic syn- dromes. Side effects involving the central nervous system are less frequent but may result in severe clinical symptoms and syndromes. The administration of chimeric antigen receptor (CAR) T cell is subject to rigorous patient selection and their use is frequently associated with neurological complications includ- ing encephalopathy and seizures, which require immediate action and appropriate therapeutic measures.
    [Show full text]
  • The Role of Molecular Mimicry in the Etiology of Guillain Barré Syndrome
    Macedonian pharmaceutical bulletin, 56 (1,2) 3 - 12 (2010) ISSN 1409 - 8695 UDC: 616.833-022 : 579.835.12.083.3 Review The role of molecular mimicry in the etiology of Guillain Barré Syndrome Aleksandra Grozdanova1*, Slobodan Apostolski2, Ljubica Suturkova1 1 Institute for Pharmaceutical chemistry, Faculty of Pharmacy, “St Cyril and Methodius” University, Skopje 2 Outpatient Neurological Clinic, Belgrade, Serbia Received: May 2011; Accepted: June 2011 Abstract Molecular mimicry between host tissue structures and microbial components has been proposed as the pathogenic mechanism for trig- gering of autoimmune diseases by preceding infection. Recent studies stated that molecular mimicry as the causative mechanism remains unproven for most of the human diseases. Still, in the case of the peripheral neuropathy Guillain-Barré syndrome (GBS) this hypothesis is supported by abundant experimental evidence. GBS is the most frequent cause of acute neuromuscular paralysis and in some cases occurs after infection with Campylobacter jejuni (C. jejuni). Epidemiological studies, showed that more than one third of GBS patients had ante- cedent C. jejuni infection and that only specific C. jejuni serotypes are associated with development of GBS. The molecular mimicry be- tween the human gangliosides and the core oligosaccharides of bacterial lipopolysaccharides (LPSs) presumably results in production of antiganglioside cross-reactive antibodies which are likely to be a contributory factor in the induction and pathogenesis of GBS. Antigan- glioside antibodies were found in the sera from patients with GBS and by sensitization of rabbits with gangliosides and C. jejuni LPSs an- imal disease models of GBS were established. GBS as prototype of post-infection immune-mediated disease probably will provide the first verification that an autoimmune disease can be triggered by molecular mimicry.
    [Show full text]
  • MSM 300 11 05 11.Pdf
    DIVISION OF HEALTH CARE FINANCING AND POLICY MEDICAID SERVICES MANUAL TABLE OF CONTENTS RADIOLOGY SERVICES 300 INTRODUCTION ...........................................................................................................................1 301 REGULATORY AUTHORITY ......................................................................................................1 302 DEFINITIONS .................................................................................................................................1 303 MEDICAID POLICY ......................................................................................................................1 303.1 RADIOLOGICAL STUDIES ..........................................................................................................1 303.1A COVERAGE AND LIMITATIONS ...............................................................................................1 303.1B PROVIDER RESPONSIBILITY.....................................................................................................2 303.1C RECIPIENT RESPONSIBILITY ....................................................................................................3 303.1D AUTHORIZATION PROCESS ......................................................................................................3 303.2 SCREENING MAMMOGRAPHY .................................................................................................3 303.2A COVERAGE AND LIMITATIONS ...............................................................................................3
    [Show full text]
  • 46 L Nursing2015 L Volume 45, Number 10 46 L
    46 l Nursing2015 l Volume 45, Number 10 www.Nursing2015.com Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. 2.0 ANCC ALCONTACT HOURSS Amyotrophic lateral sclerosis: What nurses need to know By Tamara L. Bellomo, MSN, RN-BC, and Lucille Cichminski, MSN, RN A MOTHER OF THREE teenage children, Mrs. is one of the most common neuromuscular dis- S, 49, presented to her healthcare provider eases in the world. This rapidly progressive, fatal with bilateral leg twitching and weakness, dif- neuromuscular disease involves the degeneration ficulty swallowing, and fatigue that’s worsened and death of the upper and lower motor neu- over the past few weeks. While she was on her rons.1 This article discusses the diagnosis and daily morning walk, she tripped and fell. She treatment of ALS and how nurses can help their experienced a small laceration to her leg, patients deal with the difficult diagnosis and find prompting her visit to the healthcare facility. the resources they and their families need. Her husband said that she’d had periods of slurred speech over the past few months as Who’s affected? well. She was alert and oriented, and her vital An estimated 20,000 to 30,000 Americans are signs were all within normal limits. living with ALS, and about 5,000 new cases After an exam, her healthcare provider are diagnosed each year in the United States.2 referred her to a neurologist who ordered This disease affects people of all ethnic, socio- magnetic resonance imaging (MRI), an electro- economic, and racial backgrounds.2,3 ALS most HOTOTAKE / P myogram, and a full bloodwork panel.
    [Show full text]
  • 6Th National Congress of Neuroscience Safranbolu/Karabuk-Turkey, April 09-13,2007
    NEUROANATOMY www.neuroanatomy.org VOLUME 6 [2007] Supplement 1 6th National Congress of Neuroscience Safranbolu/Karabuk-Turkey, April 09-13,2007 ABSTRACT BOOK Scientific Committee Organizing Committee Prof. Dr. Turgay DALKARA Prof.Dr. Bektas ACIKGOZ – Chairman Prof. Dr. Lutfiye EROGLU Assoc.Prof.Dr. Emine YILMAZ SIPAHI – Secretary Prof. Dr. Yucel KANPOLAT Assoc.Prof.Dr. Murat KALAYCI Prof. Dr. Fatma KUTAY Assoc.Prof.Dr. Sebnem KARGI Prof. Dr. A.Emre OGE Asst.Prof.Dr. Seyit ANKARALI Prof. Dr. Filiz ONAT Asst.Prof.Dr. Levent ATIK Prof. Dr. Cigdem OZESMI Asst.Prof.Dr. Mustafa BASARAN Prof. Dr. Gonul PEKER Asst.Prof.Dr. Rengin KOSIF Prof. Dr. Sakire POGUN Asst.Prof.Dr. Numan KONUK Prof. Dr. Ismail Hakki ULUS Asst.Prof.Dr. Aysun EROGLU UNAL Prof. Dr. Pekcan UNGAN Assoc..Prof.Dr. Ahmet GURBUZ Assoc.Prof.Dr. Pinar YAMANTURK-CELIK Asst.Prof.Dr. Nuray TURKER Assoc.Prof.Dr. Lutfiye KANIT Lect. Adnan CETINKAYA Assoc.Prof.Dr. Yasemin GURSOY-OZDEMIR Lect. Halime KARAGOL Assoc.Prof.Dr. Turker SAHINER Lect. Saban ESEN Assoc.Prof.Dr. Emine YILMAZ SIPAHI Lect. Afitap AYGUN Assoc.Prof.Dr. Emel ULUPINAR Res.Asst. Fulden ISIKDEMIR Asst.Prof.Dr. Aysun EROGLU UNAL Murat SURUCU Asst.Prof.Dr. Seyit ANKARALI Gokhan SAGLAM The conference is organized under the auspices of TUBITAK, TUBAS, BAD, Kardemir AS and Zonguldak Karaelmas University. e-ISSN 1303-1775 • p-ISSN 1303-1783 Honorary Editor Technical Editor Tuncalp Ozgen, MD M. Mustafa Aldur, MD-PhD Managing Editors Editors Mustafa Aktekin, MD-PhD M. Dogan Aksit, DVM-PhD Alp Bayramoglu, MD-PhD Ruhgun Basar, DDS-PhD M. Deniz Demiryurek, MD-PhD www.neuroanatomy.org Associate Editors A.
    [Show full text]
  • Free PDF Download
    European Review for Medical and Pharmacological Sciences 2020; 24: 8151-8159 Improvement of pure sensory mononeuritis multiplex and IgG1 deficiency with sitagliptin plus Vitamin D3 M. MAIA PINHEIRO1,2, F. MOURA MAIA PINHEIRO3, L.L. PIRES AMARAL RESENDE4, S. NOGUEIRA DINIZ2, A. FABBRI5, M. INFANTE5,6,7 1UNIVAG University Center, Várzea Grande, Mato Grosso, Brazil 2Postgraduation Program in Biotechnology and Health Innovation, Professional Master Degree in Pharmacy, Anhanguera University of São Paulo, Brazil 3Hospital de Base – FAMERP, São José do Rio Preto, Brazil 4Oncovida – Oncology and Immunology Clinic, Cuiabá, Brazil 5Endocrine Unit, CTO Hospital, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy 6Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Rome, Italy 7UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy Abstract. – INTRODUCTION: Mononeuritis CONCLUSIONS: To the best of our knowledge, multiplex (MM) is an unusual form of peripher- this is the first case showing a remarkable clin- al neuropathy involving at least two noncontig- ical improvement of MM and selective IgG1 de- uous peripheral nerve trunks. The pure sensory ficiency achieved through a combination thera- form of MM occurs rarely. Immunoglobulin (Ig)G py with sitagliptin and vitamin D3. subclass deficiency is a clinically and genetical- ly heterogeneous disorder. Up to 50% of adults Key Words: with selective subnormal IgG1 levels or selec- Mononeuritis multiplex, Mononeuropathy multi- tive IgG1 deficiency have a concomitant auto- plex, Selective IgG1 deficiency, DPP-4 inhibitors, Sita- immune disorder. Herein, we report the case of gliptin, Vitamin D, Vitamin D3, Cholecalciferol, Hypo- a patient with MM and selective IgG1 deficiency vitaminosis D.
    [Show full text]
  • Why Electromyoneurography Instead Of
    Neurological Disorders and Therapeutics Research Article ISSN: 2514-4790 Why electromyoneurography instead of electromyography and electroneurography? Electroneurography is essential for interpretation of electromyographic results! Anica Jušić* Shool of Medicine University of Zagreb, Zagreb, 10000 Zagreb, Gundulićeva 49, Croatia Abstract The author suggests revival and further development of old method who had proven to be of significant benefit in differential dignostics of nerve lesions and displayed significant research possibilities. The basic idea is the unification of electromyographic results with neural stimulation. Therefore the author suggests again, to use new name - Electromyoneurography for the old methods. Introduction electrodes as I learned at Albrecht Struppler’s laboratory. The stimulation may be done with surface electrodes also, but the reliability, George Bernard Shaw once wrote: „The single biggest problem constancy and reproducibility of the results, with such technique, in communication is the illusion that it has taken place“. I hope this decreases significantly. With needle electrodes, by simple switching introductory part will make possible, among nowadays achieved of the polarity, besides the efferent motor conduction velocity the scientific circumstances, usage and further development of methods additional afferent conduction velocity measurements can be done. If differentiated some decades ago in Centre /Institute for neuromuscular necessary, the ribbon electrodes for percutaneous evocation of sensory disease, of University Hospital Clinic Zagreb, which I have founded, potentials may be involved. 1973. The purpose of this review is to shed the light on the old methods who had proven to be of significant benefit in differential dignosis of Analyses of evoked muscle or nerve potentials clarifyes so many nerve lesions and possible basis for further scientific research.
    [Show full text]
  • FUNDELA Boletín Científico 45
    ABRIL 2013 Fundación Española para el Fomento de la Investigación de la Esclerosis Lateral Amiotrófica FUNDELA Boletín Científico 45 El boletín de FUNDELA publica resúmenes y artículos científicos referentes a los últimos avances de la investigación, tratamientos sintomáticos y cuidados al paciente con ELA. Se envía periódicamente a más de 400 suscriptores, entre los que se encuentran profesionales de la salud, pacientes y familiares de España y Latinoamérica. Todos los boletines pueden descargarse en nuestra web www.fundela.es FUNDELA no asume responsabilidades por la información que contiene este boletín. Necesitamos ayuda económica para continuar en los proyectos que indicamos a continuación •PROYECTOS PILOTO DE DETERMINACION DE DIFERENTES POSIBLES BIOMARCADORES EN PLASMA Y CELULAS MONONUCLEARES DE SANGRE PERIFERICA EN PACIENTES CON ELA •PUESTA A PUNTO DE UN ALGORITMO MOLECULAR DIAGNOSTICO EN PACIENTES CON ELA Y DEGENERACION LOBULAR FRONTOTEMPORAL •REHABILITACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA: TERAPIA OCUPACIONAL Y LOGOPEDIA •BOLETIN CIENTIFICO Actualmente contamos con subvenciones de SEALED AIR BUÑOL, Fundación MUPITI y FRANHUR, La Caixa y aportaciones particulares de pacientes y familiares que sufren la ELA. Su donativo le dará derecho a practicar una deducción en la cuota del impuesto sobre la renta. La deducción será del 25% como persona física y del 35% como empresa. Para realizar donaciones económicas pedimos suscribirse en nuestra página web: http://www.fundela.es/captaBanco.php Colaboradores voluntarios de este número: Dr. Alberto García Redondo (Bioquímico, Unidad Hospital 12 de octubre) de ELA – Hospital 12 de octubre) Dra. María Teresa Solas (Bióloga, Universidad Dra. Elena Rodríguez García (Bioquímica – Complutense) Voluntaria FUNDELA) Dra. Teresa Salas (Psicóloga, Unidad de ELA - Dr.
    [Show full text]
  • Spatial and Temporal Relationships Between Plaques and Tangles in Alzheimer-Pathology Bärbel Schönheit, Rosemarie Zarski, Thomas G
    Neurobiology of Aging 25 (2004) 697–711 Open peer commentary Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology Bärbel Schönheit, Rosemarie Zarski, Thomas G. Ohm∗,1 Department of Clinical Cell and Neurobiology, Institute of Anatomy, Charité, 10098 Berlin, Germany Received 10 September 2002; received in revised form 29 July 2003; accepted 17 September 2003 Abstract One histological hallmark in Alzheimer’s disease is the tangle. The other is the plaque. A widely discussed hypothesis is the “amyloid cascade” assuming that tangle formation is a direct consequence of amyloid plaque formation. The aim of this study was to examine plaques and tangles in a highly defined neuronal circuitry in order to determine their detailed spatial and temporal relationships. We investigated serial sections of the whole hippocampal formation of brains with early Braak-stages (0–III) for tangles only, i.e. one case at stage 0, six at stage I, six at stage II, and nine at stage III. Most cases displayed both plaques and tangles. Four cases of stages 0 and I, three cases with stage II, and even one with stage III, however, did not display plaques. In turn, no plaque was found in the absence of tangles. The spatial relationship indicates that plaques lay in the terminal fields of tangle-bearing neurons. Our analysis suggests that tangles either antecede plaques or—less likely—are independently formed. © 2004 Elsevier Inc. All rights reserved. Keywords: Alzheimer’s disease; Amyloid plaques; ␤A4-peptide; Neurofibrillary tangles; Amyloid cascade hypothesis; Hippocampal formation; Hippocampus; Entorhinal cortex; Time course; Braak staging; Anterograde neurodegeneration; Spatial pattern 1.
    [Show full text]
  • Staging of Alzheimer Disease-Associated Neurowbrillary Pathology Using Parayn Sections and Immunocytochemistry
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Springer - Publisher Connector Acta Neuropathol (2006) 112:389–404 DOI 10.1007/s00401-006-0127-z METHODS REPORT Staging of Alzheimer disease-associated neuroWbrillary pathology using paraYn sections and immunocytochemistry Heiko Braak · Irina AlafuzoV · Thomas Arzberger · Hans Kretzschmar · Kelly Del Tredici Received: 8 June 2006 / Revised: 21 July 2006 / Accepted: 21 July 2006 / Published online: 12 August 2006 © Springer-Verlag 2006 Abstract Assessment of Alzheimer’s disease (AD)- revised here by adapting tissue selection and process- related neuroWbrillary pathology requires a procedure ing to the needs of paraYn-embedded sections (5–15 m) that permits a suYcient diVerentiation between initial, and by introducing a robust immunoreaction (AT8) for intermediate, and late stages. The gradual deposition hyperphosphorylated tau protein that can be processed of a hyperphosphorylated tau protein within select on an automated basis. It is anticipated that this neuronal types in speciWc nuclei or areas is central to revised methodological protocol will enable a more the disease process. The staging of AD-related neuroW- uniform application of the staging procedure. brillary pathology originally described in 1991 was per- formed on unconventionally thick sections (100 m) Keywords Alzheimer’s disease · NeuroWbrillary using a modern silver technique and reXected the pro- changes · Immunocytochemistry · gress of the disease process based chieXy on the topo- Hyperphosphorylated tau protein · Neuropathologic graphic expansion of the lesions. To better meet the staging · Pretangles demands of routine laboratories this procedure is Introduction This study was made possible by funding from the German Research Council (Deutsche Forschungsgemeinschaft) and BrainNet Europe II (European Commission LSHM-CT-2004- The development of intraneuronal lesions at selec- 503039).
    [Show full text]
  • A Er the Wildly Successful Ice Bucket Challenge
    RESEARCH FEBRUARY/MARCH 2015 BY GINA SHAW Azer the Wildly Successful Ice Bucket Challenge ~e Ice Bucket Challenge raised big bucks on social media. Now, the ALS Association tells us where that cold, hard cash is going. As snowstorms and icy winds batter much of the country, it's hard to imagine willingly pouring a bucket of ice water over your head for any reason. But last August—when temperatures were much more forgiving—that's exactly what about 3 million people did. In an astonishing example of the power of social media, a July 31 dare from former Boston College baseball player Pete Frates, who was diagnosed with amyotrophic lateral sclerosis (ALS) in 2012, quickly went viral. The dare? Dump ice water on your head within 24 hours of being challenged or donate $100 (or whatever amount you could afford) to the ALS Association or another organization supporting ALS research. Pretty soon, the Ice Bucket Challenge meant dumping ice on your head and donating money, and everyone from your neighbor's preschooler to Bill Gates (with a custom-built ice douser), Oprah Winfrey, Jon Bon Jovi, and entire casts of Broadway shows were doing it—and posting their videos online. Even 86-year-old Ethel Kennedy took the challenge. (President Obama donated but declined the ice; actor Patrick Stewart posted a video of himself writing a check.) In La Jolla, CA, prominent ALS researcher Don Cleveland, PhD, who pioneered a novel therapy that turns off the defective genes that contribute to neurodegenerative diseases, watched the online commotion with skepticism.
    [Show full text]